Multidisciplinary perspectives for Alzheimer's and Parkinson's diseases: Hydrogels for protein delivery and cell-based drug delivery as therapeutic strategies

International Journal of Artificial Organs

Volumn 32, Issue 12, 2009, Pages 836-850

  Giordano, Carmen ^a   Albani, Diego ^b   Gloria, Antonio ^c   Tunesi, Marta ^a   Batelli, Sara ^b   Russo, Teresa ^d   Forloni, Gianluigi ^b   Ambrosio, Luigi ^c   Cigada, Alberto ^a  

^a POLITECNICO DI MILANO   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Alzheimer's disease; Cell housing; Drug delivery; Engineered cells; Hydrogels; Parkinson's disease; Recombinant proteins

Indexed keywords

CONTROLLED DRUG DELIVERY; CYTOLOGY; HOUSING; HYDROGELS; NEURODEGENERATIVE DISEASES; RECOMBINANT PROTEINS; TARGETED DRUG DELIVERY;

ALZHEIMERS DISEASE; CELL HOUSING; CELL-BASED DRUG DELIVERIES; ENGINEERED CELL; MATERIAL SCIENCE; MULTIDISCIPLINARY PERSPECTIVES; NEURODEGENERATIVE DISORDERS; PARKINSON'S DISEASE; POLYMER-BASED SYSTEMS; PROTEIN DELIVERY;

CELLS;

AGAROSE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; COLLAGEN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HEAT SHOCK PROTEIN 70; HUPERZINE A; HYALURONIC ACID; LEVODOPA; MACROGOL; METHYLCELLULOSE; NERVE GROWTH FACTOR; NEUROTROPHIN; RECOMBINANT PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; BETA SHEET; BIOENGINEERING; CELL ADHESION; CELL ENCAPSULATION; CELL SURVIVAL; CHEMICAL COMPOSITION; CROSS LINKING; CULTURE MEDIUM; DOPAMINE METABOLISM; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMBRYONIC STEM CELL; ENCAPSULATION; GENE OVEREXPRESSION; HUMAN; HYDROGEL; HYDROGEN BOND; HYDROPHOBICITY; MICROENCAPSULATION; MISSENSE MUTATION; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL TRANSPLANTATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; POLYMERIZATION; REVIEW; VISCOSITY;

EID: 74349090263     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880903201202     Document Type: Review

References (147)

1. Popovic N, Brundin P. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int J Pharm 2006; 314: 120-6.
2. Fournier E, Passirani C, Montero-Menei CN, Benoit JP. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 2003; 24: 3311-31.
3. Stabenfeldt SE, Garcia AJ, LaPlaca MC. Thermoreversible laminin-functionalized hydrogel for neural tissue engineering. J Biomed Mater Res A 2006; 77: 718-25.
4. Zhong Y, Bellamkonda RV. Biomaterials for the central nervous system. J R Soc Interface 2008; 5: 957-75.
5. Perale G, Bianco F, Giordano C, Matteoli M, Masi M, Cigada A. Engineering injured spinal cord with bone marrow-derived stem cells and hydrogel-based matrices: a glance at the state of the art. Journal of Applied Biomaterials & Biomechanics 2008; 6: 1-8.
6. Mahoney MJ, Anseth KS. Three-dimensional growth and function of neural tissue in degradable polyethylene glycol hydrogels. Biomaterials 2006; 27: 2265-74.
7. Riley MC, Fuegy PW, Firpo MA, Shu XZ, Prestwich GD, Peattie RA. Stimulation of in vivo angiogenesis using dual growth factor-loaded crosslinked glycosaminoglycan hydrogels. Biomaterials 2006; 27: 5935-43.
8. Kulkarni RV, Biswanath SA. Electrically responsive smart hydrogels in drug delivery: a review. Journal of Applied Biomaterials & Biomechanics 2007; 5: 125-39.
9. Tate MC, Shear DA, Hoffman SW, Stein DG, LaPlaca MC. Biocompatibility of methylcellulose-based constructs designed for intracerebral gelation following experimental traumatic brain injury. Biomaterials 2001; 22: 1113-23.
10. Gupta D, Tator CH, Shoichet MS. Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. Biomaterials 2006; 27: 2370-9.
11. Hamann MCJ, Tator CH, Shoichet MS. Injectable intrathecal delivery system for localized administration of EGF and FGF-2 to the injured rat spinal cord. Exp Neurol 2005; 194: 106-19.
12. Hamann MCJ, Tsai EC, Tator CH, Shoichet MS. Novel intrathecal delivery system for treatment of spinal cord injury. Exp Neurol 2003; 182: 300-9.
13. Chung C, Mesa J, Miller GJ, Randolph MA, Gill TJ, Burdick JA. Effects of auricular chondrocyte expansion on neocartilage formation in photocrosslinked hyaluronic acid networks. Tissue Eng 2006; 12: 2665-73.
14. Chung C, Mesa J, Randolph MA, Yaremchuk M, Burdick JA. Influence of gel properties on neocartilage formation by auricular chondrocytes photoencapsulated in hyaluronic acid networks. J Biomed Mater Res A 2006, 77A: 518-25.
15. Peattie RA, Rieke ER, Hewett EM, Fisher RJ, Shu XZ, Prestwich GD. Dual growth factor-induced angiogenesis in vivo using hyaluronan hydrogel implants. Biomaterials 2006; 27: 1868-75.
16. Gutowska A, Jeong B, Jasionowski M. Injectable gels for tissue engineering. Anat Rec 2001; 263: 342-9.
17. Hou S, Xu Q, Tian W, et al. The repair of brain lesion by implantation of hyaluronic acid hydrogels modified with laminin. J Neurosci Methods 2005; 148: 60-70.
18. Cui FZ, Tian WM, Hou SP, Xu QY, Lee IS. Hyaluronic acid hydrogel immobilized with RGD peptides for brain tissue engineering. J Mater Sci: Mater Med 2006; 17: 1393-401.
19. Balgude AP, Yu X, Szymanski A, Bellamkonda RV. Agarose gel stiffness determines rate of DRG neurite extension in 3D cultures. Biomaterials 2001; 22: 1077-84.
20. Mauck RL, Soltz MA, Wang CC, et al. Functional tissue engineering of articular cartilage through dynamic loading of chondrocyte-seeded agarose gels. J Biomech Eng 2000; 122: 252-60.
21. Katz JS, Burdick JA. Hydrogel mediated delivery of throphic factors for neural repair. Wiley Interdiscip Nanomed Nanobiotechnol 2009; 1: 128-39.
22. Jain A, Kim YT, McKeon RJ, Bellamkonda RV. In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury. Biomaterials 2006, 27: 497-504.
23. Bellamkonda R, Ranieri JP, Aebischer P. Laminin oligopeptide derivatized agarose gels allow threedimensional neurite extension in vitro. J Neurosci Res 1995; 41: 501-9.
24. Yu X, Dillon GP, Bellamkonda RV. A laminin and nerve growth factor-laden three-dimensional scaffold for enhanced neurite extension. Tissue Eng 1999; 5: 291-304.
25. Gilbert RJ, McKeon RJ, Darr A, Calabro A, Hascall VC, Bellamkonda RV. CS-4,6 is differentially upregulated in glial scar and is a potent inhibitor of neurite extension. Mol Cell Neurosci 2005; 29: 545-8.
26. Dodla MC, Bellamkonda RV. Anisotropic scaffolds facilitate enhanced neurite extension in vitro. J Biomed Mater Res A 2006; 78A: 213-21.
27. Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev 2002; 54: 3-12.
28. He CL, Kim SW, Lee DS. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. J Control Release 2008; 127: 189-207.
29. Chung HJ, Park TG. Self-assembled and nanostructured hydrogels for drug delivery and tissue engineering. Nano Today 2009; 4: 429-37.
30. Nguyen KT, West JL. Photopolymerizable hydrogels for tissue engineering applications. Biomaterials 2002; 23: 4307-14.
31. Yoon JJ, Chung HJ, Lee HJ, Park TG. Heparin-immobilized biodegradable scaffolds for local and sustained release of angiogenic growth factor. J Biomed Mater Res 2006; 79: 934-42.
32. Brizzolara D, Cantow HJ, Diederichs K, Keller E, Domb AJ. Mechanism of the stereocomplex formation between enantiomeric poly(lactide)s. Macromolecules 1996; 29: 191-7.
33. Jeong B, Bae YH, Kim SW. Thermoreversible gelation of PEG-PLGA-PEG triblock copolymer aqueous solutions. Macromolecules 1999; 32: 7064-9.
34. Shim WS, Yoo JS, Bae YH, Lee DS. Novel injectable pH and temperature sensitive block copolymer hydrogel. Biomacromolecules 2005; 6: 2930-4.
35. Dankers PY, Harmsen MC, Brouwer LA, van Luyn MJ, Meijer EW. A modular and supramolecular approach to bioactive scaffolds for tissue engineering. Nat Mater 2005; 4: 568-74.
36. Fusco S, Borzacchiello A, Netti PA. Perspectives on PEO-PPO-PEO triblock copolymers and their biomedical applications. J Bioact Compat Polym 2006; 21: 149-64.
37. Holmes TC. Novel peptide-based biomaterial scaffolds for tissue engineering. Trends Biotechnol 2002; 20: 16-21.
38. Pochan DJ, Schneider JP, Kretsinger J, Ozbas B, Rajagopal K, Haines L. Thermally reversible hydrogels via intramolecular folding and consequent self-assembly of a de Novo designed peptide. J Am Chem Soc 2003; 125: 11802-3.
39. Nuttelman CR, Rice MA, Rydholm AE, Salinas CN, Shah DN, Anseth KS. Macromolecular monomers for the synthesis of hydrogel niches and their application in cell encapsulation and tissue engineering. Prog Polym Sci 2008; 33: 167-79.
40. Wang C, Stewart RJ, Kopecek J. Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains. Nature 1999; 397: 417-20.
41. Chen L, Kopecek J, Stewart RJ. Responsive hybrid hydrogels with volume transitions modulated by a titin immunoglobulin module. Bioconjug Chem 2000; 11: 734-40.
42. Dove A. Cell-based therapies go live. Nat Biotechnol 2002; 20:339-43.
43. Schmidt JJ, Rowley J, Kong HJ. Hydrogels used for cell-based drug delivery. J Biomed Mater Res A 2008; 87A: 1113-22.
44. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980; 210: 908-10.
45. Aebischer P, Wahlberg L, Tresco PA, Winn SR. Macroencapsulation of dopamine-secreting cells by coextrusion with an organic polymer-solution. Biomaterials 1991; 12: 50-6.
46. Read TA, Sorensen DR, Mahesparan R, et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 2001; 19: 29-34.
47. Joki T, Machluf M, Atala A, et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 2001; 19: 35-9.
48. Orive G, De Castro M, Ponce S, et al. Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules. Mol Ther 2005; 12: 283-9.
49. Emerich DF, Winn SR, Harper J, Hammang JP, Baetge EE, Kordower JH. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons. J Comp Neurol 1994; 349: 14864.
50. Saitoh Y, Taki T, Arita N, Ohnishi T, Hayakawa T. Cell therapy with encapsulated xenogeneic tumor-cells secreting betaendorphin for treatment of peripheral pain. Cell Transplant 1995; 4:13-7.
51. Weber LM, Hayda KN, Haskins K, Anseth KS. The effects of cell-matrix interactions on encapsulated beta-cell function within hydrogels functionalized with matrix-derived adhesive peptides. Biomaterials 2007; 28: 3004-11.
52. Chang TMS. Therapeutic applications of polymeric artificial cells. Nat Rev Drug Discov 2005; 4: 221-35.
53. Gugerli R, Cantana E, Heinzen C, Von Stockar U, Marison IW. Quantitative study of the production and properties of alginate/poly-L-lysine microcapsules. J Microencapsul 2002; 19: 571-90.
54. Khademhosseini A, Eng G, Yeh J, et al. Micromolding of photocrosslinkable hyaluronic acid for cell encapsulation and entrapment. J Biomed Mater Res A 2006; 79: 522-32.
55. Weber LM, He J, Bradley B, Haskins K, Anseth KS. PEG based hydrogels as an in vitro encapsulation platform for testing controlled beta-cell microenvironments. Acta Biomater 2006; 2: 1-8.
56. Altomare L, Farè S. Cells response to topographic and chemical micropatterns. Journal of Applied Biomaterials & Biomechanics 2008; 6: 132-43.
57. Stokols S, Tuszynski MH. Freeze-dried agarose scaffolds with uniaxial channels stimulate and guide linear axonal growth following spinal cord injury. Biomaterials 2006; 27: 443-51.
58. Brooks AE, Brothers TJ, Creager MS, Lewis RV. A novel methodology to explore the viscoelasticity of spider major ampullate silk. Journal of Applied Biomaterials & Biomechanics 2007; 5: 158-65.
59. Cigada A. Biomaterials, tissue engineering, gene therapy. Journal of Applied Biomaterials & Biomechanics 2008; 6: 127-31.
60. Stokols S, Tuszynski MH. The fabrication and characterization of linearly oriented nerve guidance scaffolds for spinal cord injury. Biomaterials 2004; 25: 5839-46.
61. Campbell JJ, Bader DL, Lee DA. Mechanical loading modulates intracellular calcium signaling in human mesenchymal stem cells. Journal of Applied Biomaterials & Biomechanics 2008; 6: 9-15.
62. Goda T, Ishihara K. Soft contact lens biomaterials from bio-inspired phospholipid polymers. Expert Rev Med Devices 2006; 3: 167-74.
63. 2 hybrid materials. Journal of Applied Biomaterials & Biomechanics 2007; 5: 41-4.
64. Mishra RK, Singhal JP, Datt M, Banthia A K. Amidated pectin based hydrogels: synthesis, characterization and cytocompatibility study. Journal of Applied Biomaterials & Biomechanics 2007; 5: 88-94.
65. Oral E, Peppas NA. Hydrophilicmolecularly imprinted poly(hydroxyethyl-methacrylate) polymers. J Biomed Mater Res A 2006; 78: 205-10.
66. Draghi L, Cigada A. Nanostructured surfaces for biomedical applications. Part I: nanotopography. Journal of Applied Biomaterials & Biomechanics 2007; 5: 61-9.
67. Forsgren J, Svahn F, Jarmar T, Engqvist H. Structural change of biomimetic hydroxyapatite coatings due to heat treatment. Journal of Applied Biomaterials & Biomechanics 2007; 5: 23-7.
68. Kapur TA, Shoichet MS. Immobilized concentration gradients of nerve growth factor guide neurite outgrowth. J Biomed Mater Res A 2004; 68A: 235-43.
69. Guarino V, Causa F, Ambrosio L. Porosity and mechanical properties relationship in PCL porous scaffolds. Journal of Applied Biomaterials & Biomechanics 2007; 5: 149-57.
70. Piotrowicz A, Shoichet MS. Nerve guidance channels as drug delivery vehicles. Biomaterials 2006; 27: 2018-27.
71. Haaparanta AM, Koivurinta J, Hämääinen ER, Kellomäki M. The effect of cross-linking time on a porous freeze-dried collagen scaffold using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide as a cross-linker. Journal of Applied Biomaterials & Biomechanics 2008; 6: 89-94.
72. Morra M. Advancements in carbohydrate bioactivity and implications for the surface modification of biomaterials. Journal of Applied Biomaterials & Biomechanics 2007; 5: 1-10.
73. Moore K, Macsween M, Shoichet M. Immobilized concentration gradients of neurotrophic factors guide neurite outgrowth of primary neurons in macroporous scaffolds. Tissue Eng 2006; 12: 267-78.
74. Giannoni P, Narcisi R. Nano-approaches in cartilage repair. Journal of Applied Biomaterials & Biomechanics 2009; 7: 1-12.
75. Giordano C, Causa F, Bianco F, et al. Gene delivery systems for gene therapy in tissue engineering and central nervous system applications. Int J Artif Organs 2008; 31: 1017-26.
76. Gloria A, Russo T, De Santis R, Ambrosio L. 3D fiber deposition technique to make multifunctional and tailor-made scaffolds for tissue engineering applications. Journal of Applied Biomaterials & Biomechanics 2009; 7: 141-52.
77. Baba M, Nakajo S, Tu PH, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998; 152: 879-84.
78. Pankratz N, Foroud T. Genetics of Parkinson disease. NeuroRx 2004; 1: 235-42.
79. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-40.
80. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-7.
81. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature Genet 1998; 18: 106-8.
82. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha - synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164-73.
83. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Bjorklund A. Parkinson - like neurodegeneration induced by targeted overexpression of alpha - synuclein in the nigrostriatal system. J Neurosci 2002; 22: 2780-91.
84. Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 2008; 105: 5856-61.
85. Soldner F, Hockemeyer D, Beard C, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009; 136: 964-77.
86. Pruszak J, Isacson O. Molecular and cellular determinants for generating ES-cell derived dopamine neurons for cell therapy. Adv Exp Med Biol 2009; 651: 112-23.
87. Sugaya K, Merchant S. How to approach Alzheimer's disease therapy using stem cell technologies. J Alzheimers Dis 2008; 15: 241-54.
88. Koch P, Kokaia Z, Lindvall O, Brüstle O. Emerging concepts in neural stem cell research: autologous repair and cell-based disease modelling. The Lancet Neurology 2009; 8: 819-29.
89. Nakaji-Hirabayashi T, Kato K, Iwata H. Hyaluronic acid hydrogel loaded with genetically-engineered brain-derived neurotrophic factor as a neural cell carrier. Biomaterials 2009; 30: 4581-9.
90. Nakaji-Hirabayashi T, Kato K, Iwata H. Self-assembling chimeric protein for the construction of biodegradable hydrogels capable of interaction with integrins expressed on neural stem/progenitor cells. Biomacromolecules 2008; 9: 1411-6.
91. Moriyasu K, Yamazoe H, Iwata H. Induction dopamine releasing cells from mouse embryonic stem cells and their long-term culture. J Biomed Mater Res A 2006; 77: 136-47.
92. Thonhoff JR, Lou DI, Jordan PM, Zhao X, Wu P. Compatibility of human fetal neural stem cells with hydrogel biomaterials in vitro. Brain Res 2008; 1187: 42-51.
93. Brännvall K, Bergman K, Wallenquist U, Svahn S, Bowden T, Hilborn J, Forsberg-Nilsson K. Enhanced neuronal differentiation in a three-dimensional collagen - hyaluronan matrix. J Neurosci Res 2007; 85: 2138-46.
94. Holmes TC, de Lacalle S, Su X, Liu GS, Rich A, Zhang SG. Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds. Proc Natl Acad Sci USA 2000; 97: 6728-33.
95. Silva GA, Czeisler C, Niece KL, et al. Selective differentiation of neural progenitor cells by high-epitope density nanofibers Science 2004; 303: 1352-5.
96. Woerly S, Fort S, Pignot-Paintrand I, Cottet C, Carcenac C, Savasta M. Development of a sialic acid-containing hydrogel of poly (N-(2-hydroxypropyl) methacrylamide): characterization and implantation study. Biomacromolecules 2008; 9: 2329-37.
97. Katzman T. Senile dementia of the Alzheimer type. Ann Neurol 1983; 14: 497-506.
98. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986; 83: 4913-7.
99. Blesch A, Lu P, Tuszynski MH. Neurotrophic factors, gene therapy, and neural stem cells for spinal cord repair. Brain Research Bulletin 2002; 57: 833-8.
100. Arevalo JC, Wu SH. Neurotrophin signaling: many exciting surprises! Cell Mol Life Sci 2006; 63: 1523-37.
101. Harbaugh RE, Saunders RL, Reeder RF. Use of implantable pumps for central nervous-system drug infusions to treat neurological disease. Neurosurgery 1988; 23: 693-8.
102. Nomura H, Tator CH, Shoichet MS. Bioengineered strategies for spinal cord repair. J Neurotrauma 2006; 23: 496-507.
103. Whittlesey KJ, Shea LD. Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface. Exp Neurol 2004; 190: 1-16.
104. Anderson DG, Burdick JA, Langer R. Materials science. Smart biomaterials. Science 2004; 305: 1923-4.
105. Sawhney AS, Pathak CP, Hubbell JA. Bioerodible hydrogels based on photopolymerized poly(Ethylene Glycol)-Co-Poly(Alpha-Hydroxy Acid) diacrylate macromers. Macromolecules 1993; 26: 581-7.
106. West JL, Hubbell JA. Photopolymerized hydrogel materials for drug-delivery applications. Reactive Polymer 1995; 25: 139-47.
107. Burdick JA, Ward M, Liang E, Young MJ, Langer R. Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels. Biomaterials 2006; 27: 452-9.
108. Doh J, Irvine DJ. Photogenerated polyelectrolyte bilayers from an aqueous-processible photoresist for multicomponent protein patterning. J Am Chem Soc 2004; 126: 9170-1.
109. Katz JS, Doh J, Irvine DJ. Composition-tunable properties of amphiphilic comb copolymers containing protected methacrylic acid groups for multicomponent protein patterning. Langmuir 2006, 22: 353-9.
110. Luo Y, Shoichet MS. A photolabile hydrogel for guided three-dimensional cell growth and migration. Nature Mater 2004; 3: 249-53.
111. Luo Y, Shoichet MS. Light-activated immobilization of biomolecules to agarose hydrogels for controlled cellular response. Biomacromolecules 2004; 5: 2315-23.
112. Sakiyama-Elbert SE, Hubbell JA. Controlled release of nerve growth factor from a heparin-containing fibrin based cell ingrowth matrix. J Control Release 2000; 69:149-58.
113. Taylor SJ, McDonald JW, Sakiyama-Elbert SE. Controlled release of neurotrophin-3 from fibrin gels for spinal cord injury. J Control Release 2004; 98: 281-94.
114. Willerth SM, Johnson PJ, Maxwell DJ, et al. Rationally designed peptides for controlled release of nerve growth factor from fibrin matrices. J Biomed Mater Res A 2007; 80A: 13-23.
115. Goraltchouk A, Scanga V, Morshead CM, Shoichet MS. Incorporation of protein-eluting microspheres into biodegradable nerve guidance channels for controlled release. J Control Release 2006; 110: 400-7.
116. Mahoney MJ, Saltzman WM. Transplantation of brain cells assembled around a programmable synthetic microenvironment. Nature Biotechnol 2001; 19: 934-9.
117. Ward MS, Khoobehi A, Lavik EB, Langer R, Young MJ. Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres. J Pharm Sci Technol 2007; 96: 558-68.
118. Yu XJ, Bellamkonda RV. Tissue-engineered scaffolds are effective alternatives to autografts for bridging peripheral nerve gaps. Tissue Eng 2003; 9: 421-30.
119. Merims D, Giladi N. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord 2008; 14: 273-80.
120. Sudo J, Iwase H, Terui J, et al. Transdermal absorption of L-dopa from hydrogel in rats. Eur J Pharm Sci 1998; 7: 67-71.
121. Senthilkumar KS, Saravanan KS, Chandra G, Sindhu KM, Jayakrishnan A, Mohanakumar KP. Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism. Brain Res 2007; 184: 11-8.
122. Gao P, Xu H, Ding P, Gao Q, Sun J, Chen D. Controlled release of huperzine A from biodegradable microspheres: In vitro and in vivo studies. Int J Pharm 2007; 330: 1-5.
123. Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord 2008; 22: 116-24.
124. Singh N, Seedat F, Pillay V, Sweet JL, Danckwerts MP. Formulation and statistical optimization of novel double-incorporated PLA-PLGA microparticles within an alginate-pectinate platform for the delivery of nicotine. J Microencapsul 2006; 23: 153-67.
125. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002; 295: 865-8.
126. Auluck PK, Meulener MC, Bonini NM. Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila. J Biol Chem 2005; 280: 2873-8.
127. Dong Z, Wolfer DP, Lipp HP, Büeler H. Hsp70 gene transfer by adeno-associated virus inhibits MPTP induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol Ther 2005; 11: 80-8.
128. Yang Q, She H, Gearing M, Colla E, Lee M, Shacka JJ, Mao Z. Regulation of neuronal survival factor MEF2D by chaper-one-mediated autophagy. Science 2009; 323: 124-7.
129. Galli RL, Bielinski DF, Szprengiel A, Shukitt-Hale B, Joseph JA. Blueberry supplemented diet reverses accerelated decline in hippocampal HSP70 neuroprotection. Neurobiol Aging 2006; 27: 344-50.
130. Nagel F, Falkenburger BH, Tönges L, et al. Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease. J Neurochem 2008; 105: 853-64.
131. Batelli S, Albani D, Rametta R, et al. DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. PLoS ONE 2008; 3: e1884.
132. Benaroudj N, Fang B., Triniolles F, Ghelis C, Ladjimi MM. Overexpression in Escherichia coli, purificationand characterization of the molecular chaperone HSC70. Eur J Biochem 1993; 93: 1566-73.
133. Jindal S, Murray P, Rosenberg S, Young RA, Williams KP. Human stress protein HSP70: overexpression in E. coli, purification and characterization. Biotechnology 1995; 13: 1105-9.
134. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TATmediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005; 57: 579-96.
135. Dietz GP, Bähr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 2004; 27: 85-131.
136. Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 2006; 95: 323-48.
137. Xiong MP, Yáñez JA, Remsberg CM, et al. Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats. J Control Rel 2008; 129: 33-40.
138. Kwon HM, Kim YJ, Ryu S, Yang SI, Lee SH, Yoon BW. Differential expression of HSP70 mRNA in the mouse brain after treatment with geldanamycin. Neurol Res 2009; 31: 541-4.
139. Lee J, Tan CY, Lee SK, Kim YH, Lee KY. Controlled delivery of heat shock protein using an injectable microsphere/hydrogel combination system for the treatment of myocardial infarction. J Control Release 2009; 137: 196-202.
140. Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med 2007; 4: e262.
141. Capan Y, Jiang G, Giovagnoli S, Na KH, DeLuca PP. Preparation and characterization of poly(D,L-lactide-co-glycolide) microspheres for controlled release of human growth hormone. AAPS PharmSciTech 2003; 4: E28.
142. Chen F, Wu Z, Wang Q, Wu H, Zhang Y, Nie X, Jin Y. Preparation and biological characteristics of recombinant human bone morphogenetic protein-2-loaded dextran-co-gelatin hydrogel microspheres, in vitro and in vivo studies. Pharmacology 2005; 75: 133-44.
143. Andreopoulos FM, Persaud I. Delivery of basic fibroblast growth factor (bFGF) from photoresponsive hydrogel scaffolds. Biomaterials 2006; 27: 2468-76.
144. Aubert-Pouëssel A, Venier-Julienne MC, Clavreul A, et al. In vitro study of GDNF release from biodegradable PLGA microspheres. J Control Release 2004; 95: 463-75.
145. Gu H, Long D, Song C, Li X. Recombinant human NGF-loaded microspheres promote survival of basal forebrain cholinergic neurons and improve memory impairments of spatial learning in the rat model of Alzheimer's disease with fimbria-fornix lesion. Neuroscience Lett 2009; 453: 204-9.
146. Camarata PJ, Suryanarayanan R, Turner DA, Parker RG, Ebner TJ. Sustained release of nerve growth factor from biodegradable polymer microspheres. Neurosurgery 1992; 30: 313-9.
147. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Med 2008; 14: 504-6.